A switch in time saves more than nine
Two popular statins, Pravachol and Zocor, go generic in the summer of 2006, paving the way for significant savings.
Bargain hunters, start your engines! The cost of lowering cholesterol is dropping dramatically for anyone willing to switch from a brand-name statin to a generic version. Pravachol lost its patent protection in April, while Zocor loses its protection in late June. Several companies are poised to sell generic versions of pravastatin (the main ingredient in Pravachol) and simvastatin (the main ingredient in Zocor) at prices lower than what the brand names command. These newcomers join lovastatin — the generic form of Mevacor — which has been on the market since 2001.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.